Skip to content
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Country/Region
  • No block ID is set

  • Clinic Portal
    • +0034963905310
  • Request Information
  • +34 96 390 53 10
  • Part of brands: |
InternationalInternational
  • Country/Region
  • Part of brands: |
  • Patient Journey
    • Before Pregnancy
    • IVF Process
    • Healthy pregnancy
    • After birth
  • Reproductive Health
    • Specialists
      • ERA
      • ERA insight Hub
      • ALICE
      • EMMA
      • EndomeTRIO
      • Infertility Panels
      • EMBRACE
      • PGT-A
      • PGT-A Plus
      • PGT-M
      • PGT-SR
      • CGT
      • NACE
      • Zenit
      • POC Portfolio
      • SAT
      • Newborn Screening
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
    • Igenomix Worldwide
  • Academy
  • Blog
Genomics Precision Diagnostic > Neurology Precision Panel > Comprehensive Epilepsy Precision Panel

Comprehensive Epilepsy Precision Panel

Epilepsy is a central nervous system disease characterized by recurrent unprovoked seizures, which are brief episodes of involuntary movement that may involve a part of the body (partial) or the entire body (generalized) and can be accompanied by loss of consciousness and loss of control of bowel or bladder function.
Overview
Indication
Clinical Utility
Genes & Diseases
Methodology
References

Overview

  • Epilepsy is a central nervous system disease characterized by recurrent unprovoked seizures, which are brief episodes of involuntary movement that may involve a part of the body (partial) or the entire body (generalized) and can be accompanied by loss of consciousness and loss of control of bowel or bladder function. Around 50 million people worldwide have epilepsy, making it one of the most common neurological diseases globally. Epilepsy entails an enduring predisposition to generate neurobiological, cognitive, psychological and social consequences. Multiple risk factors exist for epilepsy one of them being a strong genetic predisposition. The three major classes of epilepsy disorders are genetic generalized, focal and encephalopathic epilepsies, with several specific disorders within each class.Epilepsy genetics is shifting from an academic pursuit to a clinical discipline based on molecular diagnosis and stratified medicine. Mutations leading to epilepsy have been identified in genes encoding ion channels, neurotransmitter receptors, molecular cascade of cellular energy production and proteins involved in neuronal excitability. The mode of inheritance ranges from autosomal dominant, recessive all the way to mitochondrial.

  • The IgenomixComprehensive EpilepsyPrecision Panel can serve as an accurate and directed diagnostic toolas well as for a differential diagnosis of recurrent seizures ultimately leading to a better management and prognosis of the disease. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes involved.

Indication

  • The Igenomix Comprehensive EpilepsyPrecision Panel is indicated in patients with a clinical suspicion or diagnosis presenting with the following manifestations:

    • Family history of epilepsy or treatment-resistant seizures 
    • Disturbances of movement 
    • Vision, hearing and taste disturbances 
    • Temporary confusion 
    • Uncontrollable jerking movements of the arms and legs 
    • Fear, anxiety or deja vu 
    • Loss of consciousness or awareness 

Clinical Utility

The clinical utility of this panel is: 

  • The genetic and molecular diagnosis for an accurate clinical diagnosis of a symptomatic patient.  
  • Early initiation of treatment with a multidisciplinary team in the form of medical with antiepileptic medication and monitoring of side effects, epilepsy surgery if indicated and dietary modifications. 
  • Establish recurrence risk depending on the type of epilepsy, genetic background and clinical presentation.  
  • Risk assessment and genetic counselling of asymptomatic family members according to the mode of inheritance. 
  • Improvement of delineation of genotype-phenotype correlation.

Genes & Diseases

Methodology

References

See scientific referrals

Symonds, J. D., Zuberi, S. M., & Johnson, M. R. (2017). Advances in epilepsy gene discovery and implications for epilepsy diagnosis and treatment. Currentopinion in neurology, 30(2), 193–199. https://doi.org/10.1097/WCO.0000000000000433

Thijs, R. D., Surges, R., O’Brien, T. J., & Sander, J. W. (2019). Epilepsy in adults. Lancet (London, England), 393(10172), 689–701. https://doi.org/10.1016/S0140-6736(18)32596-0

Hebbar, M., &Mefford, H. C. (2020). Recent advances in epilepsy genomics and genetic testing. F1000Research, 9, F1000 Faculty Rev-185. https://doi.org/10.12688/f1000research.21366.1

Myers, C. T., &Mefford, H. C. (2015). Advancing epilepsy genetics in the genomic era. Genome medicine, 7(1), 91. https://doi.org/10.1186/s13073-015-0214-7

Weber, Y. G., Biskup, S., Helbig, K. L., Von Spiczak, S., &Lerche, H. (2017). The role of genetic testing in epilepsy diagnosis and management. Expert review of molecular diagnostics, 17(8), 739–750. https://doi.org/10.1080/14737159.2017.1335598

Gurnett, C. A., & Hedera, P. (2007). New ideas in epilepsy genetics: novel epilepsy genes, copy number alterations, and gene regulation. Archives of neurology, 64(3), 324–328. https://doi.org/10.1001/archneur.64.3.324

Stafstrom, C. E., &Tempel, B. L. (2000). Epilepsy genes: the link between molecular dysfunction and pathophysiology. Mental retardation and developmental disabilities research reviews, 6(4), 281–292. https://doi.org/10.1002/1098-2779(2000)6:4<281::AID-MRDD7>3.0.CO;2-9

Goodkin, H. (2009). The founding of the American Epilepsy Society: 1936. Epilepsia, 50(3), 566-570. doi: 10.1111/j.1528-1167.2008.01910.x

Berg, A., Berkovic, S., Brodie, M., Buchhalter, J., Cross, J., & van Emde Boas, W. et al. (2010). Revised terminology and concepts for organization of seizures and epilepsies: Report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia, 51(4), 676-685. doi: 10.1111/j.1528-1167.2010.02522.x

descargar

Detail description

Download

Request Information

WE GUIDE YOU

Fertility
Inherited diseases prevention
Healthy pregnancy

To see the accreditation certificate, associated technical annex and list of accredited tests, click on this link.

OUR SERVICES

Genetic testing solutions
For patients
How to send a sample?
User manual

ABOUT US

About Igenomix
Contact
Quality
Complaints
Work with us
Terms and conditions

FOLLOW IGENOMIX

  + 96 390 53 10
  Write us
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
Country/Region

[2024] © Igenomix Privacy Page Quality policy Legal note Cookies policy

Request Information


  • Patient Journey
    • Before Pregnancy
    • IVF Process
    • Healthy pregnancy
    • After birth
  • Reproductive Health
    • Specialists
      • ERA
      • ERA insight Hub
      • ALICE
      • EMMA
      • EndomeTRIO
      • Infertility Panels
      • EMBRACE
      • PGT-A
      • PGT-A Plus
      • PGT-M
      • PGT-SR
      • CGT
      • NACE
      • Zenit
      • POC Portfolio
      • SAT
      • Newborn Screening
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
    • Igenomix Worldwide
  • Academy
  • Blog
  • Country/Region
  • +34 96 390 53 10
  • Clinic Portal
  • Request Information